Citeline Clinical’s Post

Before filling your prescriptions, it's important to consider the cost difference between generic and brand-name medications. For example, Gleevec, a cancer medication, costs around $10k for a month's supply, while its generic equivalent is around $60. By switching to generics, you could save a significant amount, making healthcare more affordable without compromising quality. ✅ Follow us for more tips on how to save on your medications! #bigpharma #pharma #healthcare #healthinsurance #prescriptions #genericmedicine #americanhealthcare #dirx #dirxhealth

New in today's Radar on Drug Benefits: The rumored new regs that could help payers and PBMs streamline digital therapeutics, state PBM regulation in the spotlight, how expiring policies threaten opioid use disorder med uptake, and more top stories. #Pipeline2Patient Norstella https://hubs.ly/Q02v3YLT0

Another major milestone in medical advancement was made last night! The FDA has granted accelerated approval to the first drug ever to treat moderate to advanced NASH, a condition that can lead to extensive and irreversible liver scarring and damage and ultimately death. The approved drug, resmetirom tablet, now branded as Rezdiffra, developed by Madrigal Pharmaceuticals, has demonstrated impressive results in the pivotal Phase 3 program. >80% of moderate to advanced NASH patients treated with Rezdiffra achieved fibrosis reversal or no fibrosis progression. What's more, the FDA has given Rezdiffra, a once-daily pill, a fantastic label that requires no biopsy for determining the stage of disease, has no contraindications, no boxed warning, and no monitoring requirements beyond the standard of care. With this approval, doctors will now at last have an effective and safe tool to treat the ca. half a million patients in the U.S. diagnosed with moderate to advanced NASH who would otherwise face a bleak future. Madrigal has furthermore priced Rezdiffra within the cost-effectiveness threshold range, as suggested by the independent organization ICER, which should facilitate broad insurance coverage. This is a huge win for medical science and the patients who have been waiting for a solution for so long. #nash, #liverdisease, #fattyliverdisease, #medicaladvancements

Why is early diagnosis of Alzheimer's so important? With September being #WorldAlzheimersMonth it is crucial to discuss how people with Alzheimer’s can receive personalized, multimodal care and support to delay the deterioration of their functional status and quality of life and alleviate the burden imposed on their care partners. Read the blog by Clara Ricci, Senior Medical Writer at Clarivate to explore the challenges associated with early Alzheimer‘s diagnosis, and the opportunities for pharmaceutical companies to support those impacted by the disease, here: https://lnkd.in/ekU84yca #HealthcareInnovation #AlzheimersDisease #EarlyDiagnosis #BetterCare

#DYK about 16 million Americans experience gastroparesis symptoms, and the majority go untreated as there is no chronic treatment option?     CinDome Pharma is enrolling the #envision3d clinical trial to investigate deudomperidone (CIN-102) as a potential, chronic therapy for gastroparesis and fill this unmet medical need. Learn more about our work at: cindome.com and www.gastroparesistrial.com #GastroparesisAwarenessMonth #GastroparesisAwareness #LivingWithGP 

Johnson & Johnson's Nipocalimab Hits $6.5B Milestone in Autoimmune Therapy Triumph   Johnson & Johnson's Nipocalimab has soared through its phase 3 trial, marking a pivotal moment in the pursuit of autoimmune therapy excellence. With regulators on the horizon, can Nipocalimab revolutionize treatment paradigms for myasthenia gravis and beyond? Read more about this article in the comments below. #biopharma #innovation #autoimmune #therapies #clinicaltrials #healthcare #advancements #jnj #medical #regulatoryapproval

To Be or Not to Be? The Turning Point for Psychedelics in Healthcare August 11th, 2024, could mark a historic moment in global healthcare. The U.S., the same country that launched the War on Drugs, is now on the verge of potentially introducing MDMA as a treatment for PTSD. Whether or not the FDA approves, this event signals a significant shift. This paradigm shift challenges Big Pharma, as MDMA-assisted therapy (MDMA-AT) relies on an open-source molecule, prompting a rethinking of treatment models. While Australia has already adopted psychedelic-assisted therapy based on U.S. trials, the EU faces a more complex path due to its diverse regulatory landscape. The Dutch state commission’s Beyond Ecstasy report highlights that, despite high MDMA use in the Netherlands, related deaths remain low, thanks to effective harm reduction practices. This positions the Netherlands as a leader in the EU’s drug policy and research. However, the reality remains: more research is needed before the EU can widely adopt MDMA-AT. Instead of waiting for U.S. decisions to dictate policy, we should focus on sharing knowledge, driving research, and ethically implementing these innovative treatments within the EU. As we navigate this psychedelic renaissance, the question is not just whether this shift will happen but how we can ensure it’s done responsibly and effectively.

💥There were 9 Key Digital Therapeutics (DTx) Developments in April 2024 🌅See infographic slide below with the summaries, along with therapeutic area and news category key 🧠4 in Mental Health and 💗3 in Cardiovascular show these areas are still dominating the development focus ✅4 approvals (3 FDA and one in India) #DigitalHealth #DTx

Nearly 13 million adults in the U.S. suffer from #IBSD. In recognition of #IBSAwarenessMonth, we continue raising awareness of the need for better therapeutic options for #IBSD that are safe, effective & convenient to effectively manage this chronic and debilitating condition.      CinRx portfolio company CinPhloro Pharma is working to address this need with CIN-103, a program in Phase 2 clinical investigation for chronic IBS-D.     Learn more about CinPhloro at https://lnkd.in/gNfzEtTM and the ongoing IBS-D clinical trial at https://lnkd.in/dMNaA-cg  

Navigating Growth: #US #Multiple #Sclerosis #Drugs #Market Analysis (2024-2030) Get Free PDF: https://lnkd.in/dy5BTC5u Discover insights into the evolving landscape of the US Multiple Sclerosis Drugs Market from 2024 to 2030. With a projected growth rate of 2.1% annually, reaching USD 12.17 billion by 2030, this comprehensive report sheds light on the factors driving market expansion. Explore the dynamics of this chronic CNS disorder, its prevalence, and the critical role of pharmaceutical interventions in managing symptoms. Stay informed to navigate opportunities and challenges in this vital healthcare sector. #MultipleSclerosis #Healthcare #MarketAnalysis